Propranolol in the treatment of infantile haemangiomas: Lessons from the European Propranolol In the Treatment of Complicated Haemangiomas (PITCH) Taskforce Survey.
Item Type:Journal Article
Citation:Wedgeworth E, Glover M, Irvine AD, Neri I, Baselga Torres E, Clayton TH, Beattie PE, Bjerre JV, Burrows NP, Foelster-Holst R, Hedelund L, Hernandez-Martin A, Audrain H, Bhate K, Brown SJ, Baryschpolec S, Darne S, Durack A, Dvorakova V, Gach J, Goldstraw N, Goodyear H, Grabcyznska S, Greenblatt D, Halpern J, Hearn RM, Hoey S, Hughes B, Jayaraj R, Johansson EK, Lam M, Leech S, O'Regan GM, Morrison D, Porter W, Ramesh R, Schill T, Shaw L, Taylor AE, Taylor R, Thomson J, Tiffin P, Tsakok M, Janmohamed SR, Laguda B, McPherson T, Oranje A, Patrizi A, Ravenscroft J, Shahidullah H, Soloman L, Svensson A, Wahlgren CF, Hoeger PH, Flohr C, Propranolol in the treatment of infantile haemangiomas: Lessons from the European Propranolol In the Treatment of Complicated Haemangiomas (PITCH) Taskforce Survey., The British journal of dermatology, 2015
PMID 26473312 PITCH survey BJD.pdf (PDF) 221.0Kb
BACKGROUND: Oral propranolol is widely prescribed as first line treatment for infantile haemangiomas (IHs) and anecdotally prescribing practice differs widely between centres. OBJECTIVES: The Propranolol In the Treatment of Complicated Haemangiomas (PITCH) Taskforce was founded to establish patterns of use of propranolol in IHs. METHODS: Participating centres entered data on all of their patients who had completed treatment with oral propranolol for IHs, using an online data capture tool. RESULTS: The study cohort comprised 1096 children from 39 centres in eight European countries. 76.1% were female and 92.8% had a focal IH, with the remainder showing a segmental, multifocal or indeterminate pattern. The main indications for treatment were periocular location (29.3%), risk of cosmetic disfigurement (21.1%), and ulceration and bleeding (20.6%). 69.2% of patients were titrated up to a maintenance regimen, which consisted of 2mg/kg/day (85.8%) in the majority of cases. 91.4% of patients had an excellent or good response to treatment. Rebound growth occurred in 14.1% upon stopping, of which 53.9% were restarted and treatment response was recaptured in 91.6% of cases. While there was no significant difference in the treatment reponse, comparing a maintenance dose of <2mg/kg/day versus 2mg/kg/day versus >2mg/kg/day, the risk of adverse events was significantly higher (OR=1 vs adjusted OR=0.70 (0.33-1.50), p=0.36 vs 2.38 (1.04-5.46), p=0.04, ptrend <0.001). CONCLUSIONS: The PITCH survey summarises the use of oral propranolol across 39 European centres, in a variety of IH phases and could be used to inform treatment guidelines and the design of an intervention study. This article is protected by copyright. All rights reserved.
Author: IRVINE, ALAN
Type of material:Journal Article
Series/Report no:The British journal of dermatology
Availability:Full text available